Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis

Journal of Hepatology

Volumn 58, Issue 2, 2013, Pages 329-334

  Al Mamari, Said ^a   Djordjevic, Jelena ^a   Halliday, John S ^a   Chapman, Roger W ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cholangiocarcinoma; Primary sclerosing cholangitis; Serum alkaline phosphatase

Indexed keywords

ALKALINE PHOSPHATASE; URSODEOXYCHOLIC ACID;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILE DUCT CARCINOMA; CANCER RISK; CHOLANGIOGRAPHY; CONTROLLED STUDY; DATA BASE; DEATH; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL;

ADULT; ALKALINE PHOSPHATASE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOLOGICAL MARKERS; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84872409616     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.10.013     Document Type: Article

References (44)

1. R.W. Chapman, B.A. Arborgh, J.M. Rhodes, J.A. Summerfield, R. Dick, and P.J. Scheuer Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology Gut 21 1980 870 877
2. J.R.L. Maggs, and R.W. Chapman An update on primary sclerosing cholangitis Curr Opin Gastroenterol 24 2008 377 383
3. R.W. Chapman Risk factors for biliary tract carcinogenesis Ann Oncol 10 1999 S308 S311
4. G.J. Gores Early detection and treatment of cholangiocarcinoma Liver Transpl 6 2000 s30 s34
5. K. Burak, P. Angulo, T.M. Pasha, K. Egan, J. Petz, and K.D. Lindor Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis Am J Gastroenterol 99 2004 523 526
6. K.M. Boberg, A. Bergquist, S. Mitchell, A. Pares, F. Rosina, and U. Broomé Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation Scand J Gastroenterol 37 2002 1205 1211
7. C. Levy, and K.D. Lindor Primary sclerosing cholangitis: epidemiology, natural history, and prognosis Semin Liver Dis 26 2006 030
8. K.M. Boberg, G. Rocca, T. Egeland, A. Bergquist, U. Broomé, and L. Caballeria Time-dependent Cox regression model is superior in prediction of prognosis in 21primary sclerosing cholangitis Hepatology 35 2002 652 657
9. J.J.W. Tischendorf, H. Hecker, M. Kruger, M.P. Manns, and P.N. Meier Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study Am J Gastroenterol 102 2007 107 114
10. J.A. Talwalkar, and K.D. Lindor Natural history and prognostic models in primary sclerosing cholangitis Best Pract Res Clin Gastroenterol 15 2001 563 575
11. W.R. Kim, J.J. Poterucha, R.H. Wiesner, N.F. LaRusso, K.D. Lindor, and J. Petz The relative role of the child-pugh classification and the mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis Hepatology 29 1999 1643 1648
12. E. Solano, A. Khakhar, M. Bloch, D. Quan, V. McAlister, and C. Ghent Liver transplantation for primary sclerosing cholangitis Transpl Proc 35 2003 2431 2434
13. W.R. Kim, T.M. Therneau, R.H. Wiesner, J.J. Poterucha, J.T. Benson, and M. Malinchoc A revised natural history model for primary sclerosing cholangitis Mayo Clin Proc 75 2000 688 694
14. K.D. Lindor Ursodiol for primary sclerosing cholangitis N Engl J Med 336 1997 691 695
15. R. Olsson, K.M. Boberg, O. Schaffalitsky de Muckadell, S. Lindgren, R. Hultcrantz, and G. Folvik High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study Gastroenterology 129 2005 1464 1472
16. R.E. Poupon, A.-M. Bonnand, Y. Chrétien, and R. Poupon Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis Hepatology 29 1999 1668 1671
17. A. Parés, L. Caballería, and J. Rodés Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid Gastroenterology 130 2006 715 720
18. P. Angulo, K.P. Batts, T.M. Therneau, R.A. Jorgensen, E.R. Dickson, and K.D. Lindor Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis Hepatology 29 1999 644 647
19. K.D. Lindor, K.V. Kowdley, V.A.C. Luketic, M.E. Harrison, T. McCashland, and A.S. Befeler High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis Hepatology 50 2009 808 814
20. U. Beuers, U. Spengler, W. Kruis, ü. Aydemir, B. Wiebecke, and W. Heldwein Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial Hepatology 16 1992 707 714
21. S.A. Mitchell, D.S. Bansi, N. Hunt, K. von Bergmann, K.A. Fleming, and R.W. Chapman A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis Gastroenterology 121 2001 23
22. O. Chazouillères, R. Poupon, J.-P. Capron, E.-H. Metman, D. Dhumeaux, and M. Amouretti Ursodeoxycholic acid for primary sclerosing cholangitis J Hepatol 11 1990 120 123
23. D.M. Harnois, P. Angulo, R.A. Jorgensen, N.F. LaRusso, and K.D. Lindor High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis Am J Gastroenterol 96 2001 1558 1562
24. C.B. O'Brien, J.R. Senior, R. Arora-Mirchandani, A.K. Batta, and G. Salen Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study Hepatology 14 1991 838 847
25. A. Stiehl Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis Scand J Gastroenterol 29 1994 59 61
26. S.N. Cullen, C. Rust, K. Fleming, C. Edwards, U. Beuers, and R.W. Chapman High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective J Hepatol 48 2008 792 800
27. L. Okolicsanyi, M. Groppo, A. Floreani, A.M. Morselli-Labate, A.G. Rusticali, and A. Battocchia Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey Dig Liver Dis 35 2003 325 331
28. P.P. Stanich, E. Björnsson, A.A. Gossard, F. Enders, R. Jorgensen, and K.D. Lindor Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis Dig Liver Dis 43 2011 309 313
29. J. Ludwig, E.R. Dickson, and G.S.A. McDonald Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) Virchows Arch 379 1978 103 112
30. M.H. Imam, E. Sinakos, A.A. Gossard, K.V. Kowdley, V.A.C. Luketic, and M. Edwyn Harrison High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis Aliment Pharmacol Ther 34 2011 1185 1192
31. J.E. Eaton, M.G. Silveira, D.S. Pardi, E. Sinakos, K.V. Kowdley, and V.A.C. Luketic High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis Am J Gastroenterol 106 2011 1638 1645
32. European Association for the Study of the Liver Diseases EASL clinical practice guidelines: management of cholestatic liver diseases J Hepatol 51 2009 237 267
33. G.M. Hirschfield, E.J. Heathcote, and M.E. Gershwin Pathogenesis of cholestatic liver disease and therapeutic approaches Gastroenterology 139 2010 1481 1496
34. A. Bergquist, A. Ekbom, R. Olsson, D. Kornfeldt, L. Lööf, and Å. Danielsson Hepatic and extrahepatic malignancies in primary sclerosing cholangitis J Hepatol 36 2002 321 327
35. T.J. Weismüller, J. Wedemeyer, S. Kubicka, C.P. Strassburg, and M.P. Manns The challenges in primary sclerosing cholangitis-aetiopathogenesis, autoimmunity, management and malignancy J Hepatol 48 2008 S38 S57
36. A. Bergquist, H. Glaumann, B. Persson, and U. Broomé Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study Hepatology 27 1998 311 316
37. N. Chalasani, A. Baluyut, A. Ismail, A. Zaman, G. Sood, and R. Ghalib Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study Hepatology 31 2000 7 11
38. B. Brandsæter, H. Isoniemi, U. Broomé, M. Olausson, L. Bäckman, and B. Hansen Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy J Hepatol 40 2004 815 822
39. J. Ludwig Small-duct primary sclerosing cholangitis Semin Liver Dis 11 1991 27
40. W.R. Kim, J. Ludwig, and K.D. Lindor Variant forms of cholestatic diseases involving small bile ducts in adults Am J Gastroenterol 95 2000 1130 1138
41. U. Broomé, H. Glaumann, E. Lindstöm, L. Lööf, S. Almer, and H. Prytz Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC) J Hepatol 36 2002 586 589
42. E. Björnsson, K.M. Boberg, S. Cullen, K. Fleming, O.P. Clausen, and O. Fausa Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis Gut 2002 731 735
43. P. Angulo, Y. Maor-Kendler, and K.D. Lindor Small-duct primary sclerosing cholangitis: a long-term follow-up study Hepatology 35 2002 1494 1500
44. E. Björnsson, R. Olsson, A. Bergquist, S. Lindgren, B. Braden, and R.W. Chapman The natural history of small-duct primary sclerosing cholangitis Gastroenterology 134 2008 975 980